Fingerprint
- 1 Similar Profiles
Grants & Projects
- 15 Finished
-
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Schuster, M. (PI), Gabig, T. (CoPI), Lan, F. (CoPI), Kiner-Strachan, B. (CoPI) & Salman, H. (CoPI)
09/13/17 → 08/14/20
Project: Research
-
A Two-Stage, Open-Label Followed by Placebo-Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients with IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated with Hypomethylating Agents
Gabig, T. (CoPI), Lan, F. (CoPI), Schuster, M. (CoPI), Salman, H. (PI) & Kiner-Strachan, B. (CoPI)
09/13/17 → 07/23/19
Project: Research
-
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
Schuster, M. (PI), Gabig, T. (CoPI), Jandl, T. (CoPI), Lan, F. (CoPI), Kiner-Strachan, B. (CoPI) & Salman, H. (CoPI)
08/23/17 → 05/3/24
Project: Research
-
Bristol-Meyers Squibb: Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Myeliod Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
Schuster, M. (PI), Gabig, T. (CoPI), Lan, F. (CoPI), Kiner-Strachan, B. (CoPI) & Salman, H. (CoPI)
08/18/17 → 07/23/19
Project: Research
-
Start Up Fees: Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic
Schuster, M. (PI), Gabig, T. (CoPI), Lan, F. (CoPI) & Kiner-Strachan, B. (CoPI)
09/13/16 → 09/12/17
Project: Research
-
ras oncogene mediates paracrine interactions between leukemic progenitor cells and stromal elements
Derigs, H. G., Nahreini, T. S., Harrington, M. A., Burgess, G. S., English, D., Inhorn, L., Klingberg, D., Gabig, T. G. & Boswell, H. S., Jan 1 2018, Growth Regulation and Carcinogenesis: Volume I. CRC Press, p. 267-278 12 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer
Gabig, T. G., Waltzer, W. C., Whyard, T. & Romanov, V., Sep 16 2016, In: Biochemical and Biophysical Research Communications. 478, 2, p. 887-892 6 p.Research output: Contribution to journal › Article › peer-review
11 Scopus citations -
Refractory adult primary autoimmune neutropenia that responded to alemtuzumab
Neerukonda, A. R., Lan, F., Gabig, T. & Saraya, T., 2016, In: Internal Medicine. 55, 12, p. 1667-1670 4 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
A claudin 3 and claudin 4-targeted clostridium perfringens protoxin is selectively cytotoxic to PSA-producing prostate cancer cells
Romanov, V., Whyard, T. C., Waltzer, W. C. & Gabig, T. G., Sep 1 2014, In: Cancer Letters. 351, 2, p. 260-264 5 p.Research output: Contribution to journal › Article › peer-review
28 Scopus citations -
MOZ and MOZ-CBP cooperate with NF-κB to activate transcription from NF-κB-dependent promoters
Chan, E. M., Chan, R. J., Comer, E. M., Goulet, R. J., Crean, C. D., Brown, Z. D., Fruehwald, A. M., Yang, Z., Boswell, H. S., Nakshatri, H. & Gabig, T. G., Dec 2007, In: Experimental Hematology. 35, 12, p. 1782-1792 11 p.Research output: Contribution to journal › Article › peer-review
Open Access26 Scopus citations